LUNG CANCER

Latest News

Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC
Coformulation of Pembrolizumab/Vibostolimab Fails to Show PFS Benefit in NSCLC

March 20th 2023

The phase 3 KeyVibe-002 trial of pembrolizumab and vibostolimab did not meet its primary end point of progression-free survival and was numerically less effective than docetaxel in patients with non–small cell lung cancer

Husain Discusses Role of Osimertinib in Non–Small Cell Lung Cancer
Husain Discusses Role of Osimertinib in Non–Small Cell Lung Cancer

March 18th 2023

Pembrolizumab Plus Chemotherapy Prolongs OS in Advanced Mesothelioma
Pembrolizumab Plus Chemotherapy Prolongs OS in Advanced Mesothelioma

March 13th 2023

Phase 1b/2a Trial of Bemcentinib and SOC Doses First Patient With STK11m NSCLC
Phase 1b/2a Trial of Bemcentinib and SOC Doses First Patient With STK11m NSCLC

March 11th 2023

Streamlining NGS Testing Process Improves Turnaround Time in NSCLC
Streamlining NGS Testing Process Improves Turnaround Time in NSCLC

March 9th 2023

Video Series
Video Interviews
Podcasts

More News